TheraCryf (LSE:TCF) Total Liabilities: £1.82 Mil (As of Sep. 2025)


What is TheraCryf Total Liabilities?

TheraCryf LSE:TCF Total Liabilities is £1.82 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's Total Liabilities for the quarter that ended in Sep. 2025 was £1.82 Mil.

TheraCryf's quarterly Total Liabilities increased from Sep. 2024 (£0.47 Mil) to Mar. 2025 (£1.66 Mil) and increased from Mar. 2025 (£1.66 Mil) to Sep. 2025 (£1.82 Mil).

TheraCryf's annual Total Liabilities declined from Mar. 2023 (£0.83 Mil) to Mar. 2024 (£0.72 Mil) but then increased from Mar. 2024 (£0.72 Mil) to Mar. 2025 (£1.66 Mil).

TheraCryf Total Liabilities Historical Data

* Premium members only.

The historical data trend for TheraCryf's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Total Liabilities Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.41 0.83 0.72 1.66

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.72 0.47 1.66 1.82

TheraCryf Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TheraCryf's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.662+(0+-0.00099999999999989
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.66

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=7.63-5.969
=1.66

TheraCryf's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.816+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.82

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=6.618-4.802
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of £1.82 Mil mean?
TheraCryf (LSE:TCF) has a Total Liabilities of £1.82 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TheraCryf and its competitors.
Is TheraCryf's Total Liabilities too high?
TheraCryf's current Total Liabilities is £1.82 Mil.
How does TheraCryf's Total Liabilities compare to VRTX and REGN?
TheraCryf's Total Liabilities of £1.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TheraCryf and its competitors. TheraCryf's current Total Liabilities is £1.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Total Liabilities of £1.82 Mil. The current Total Liabilities is £1.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Total Liabilities is £1.82 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.